

# Scott A Waldman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/774846/publications.pdf>

Version: 2024-02-01

318  
papers

10,520  
citations

28274

55  
h-index

51608

86  
g-index

320  
all docs

320  
docs citations

320  
times ranked

9046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 7661-7664.	7.1	482
2	Cardiopoietic Stem Cell Therapy in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2329-2338.	2.8	427
3	Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men. Antimicrobial Agents and Chemotherapy, 2002, 46, 739-745.	3.2	239
4	Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 14827-14832.	7.1	180
5	Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochemical Pharmacology, 1986, 35, 3525-3531.	4.4	149
6	Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal, 2017, 38, ehw543.	2.2	148
7	Antiobesity Pharmacotherapy: New Drugs and Emerging Targets. Clinical Pharmacology and Therapeutics, 2013, 95, 53-66.	4.7	147
8	Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7846-7851.	7.1	143
9	Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends in Biotechnology, 2007, 25, 145-152.	9.3	140
10	Pharmacokinetics of Ertapenem in Healthy Young Volunteers. Antimicrobial Agents and Chemotherapy, 2002, 46, 3506-3511.	3.2	137
11	Bacterial enterotoxins are associated with resistance to colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2695-2699.	7.1	131
12	A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. Journal of Clinical Investigation, 2011, 121, 3578-3588.	8.2	130
13	Exposure-Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice. Journal of Clinical Pharmacology, 2003, 43, 831-839.	2.0	127
14	Effect of In Vivo Nitroglycerin Therapy on Endothelium-Dependent and Independent Vascular Relaxation and Cyclic GMP Accumulation in Rat Aorta. Journal of Cardiovascular Pharmacology, 1987, 10, 371-378.	1.9	125
15	Guanylyl Cyclase C Suppresses Intestinal Tumorigenesis by Restricting Proliferation and Maintaining Genomic Integrity. Gastroenterology, 2007, 133, 599-607.	1.3	124
16	First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2003, 111, S835-S842.	2.9	123
17	Chronic Diseases: The Emerging Pandemic. Clinical and Translational Science, 2011, 4, 225-226.	3.1	115
18	Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients. Hypertension, 1995, 25, 37-46.	2.7	114

#	ARTICLE	IF	CITATIONS
19	Single-Dose Pharmacokinetics of Indinavir and the Effect of Food. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 332-338.	3.2	113
20	Biochemical Mechanisms Underlying Vascular Smooth Muscle Relaxation. <i>Journal of Cardiovascular Pharmacology</i> , 1988, 12, 115-118.	1.9	113
21	Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. <i>Human Pathology</i> , 2005, 36, 170-179.	2.0	109
22	Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 745.	7.4	102
23	Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update. <i>Circulation</i> , 2013, 128, 2813-2851.	1.6	100
24	Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. <i>Cancer Immunology Research</i> , 2018, 6, 509-516.	3.4	100
25	Atriopeptin II elevates cyclic GMP, activates cyclic GMP-dependent protein kinase and causes relaxation in rat thoracic aorta. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1985, 846, 179-184.	4.1	99
26	Homeostatic Control of the Crypt-Villus Axis by the Bacterial Enterotoxin Receptor Guanylyl Cyclase C Restricts the Proliferating Compartment in Intestine. <i>American Journal of Pathology</i> , 2007, 171, 1847-1858.	3.8	99
27	Guanylyl Cyclase C Messenger RNA Is a Biomarker for Recurrent Stage II Colorectal Cancer. <i>Annals of Internal Medicine</i> , 1999, 131, 805.	3.9	96
28	Potential for Interactions between Caspofungin and Nelfinavir or Rifampin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4306-4314.	3.2	93
29	Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. <i>Annals of Oncology</i> , 2017, 28, 2135-2141.	1.2	92
30	Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 37-42.	7.1	91
31	Inhibition of Nitric Oxide Biosynthesis Promotes P-selectin Expression in Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 2068-2075.	2.4	90
32	Effects of Glyceryl Trinitrate on Endothelium-Dependent and -Independent Relaxation and Cyclic GMP Levels in Rat Aorta and Human Coronary Artery. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 10, 82-89.	1.9	89
33	Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP levels and relaxation in rat aorta. <i>European Journal of Pharmacology</i> , 1985, 115, 219-229.	3.5	88
34	Bile Acids Induce Ectopic Expression of Intestinal Guanylyl Cyclase C Through Nuclear Factor- $\kappa$ B and Cdx2 in Human Esophageal Cells. <i>Gastroenterology</i> , 2006, 130, 1191-1206.	1.3	87
35	Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 291-300.	2.0	86
36	Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. <i>Clinical Therapeutics</i> , 2003, 25, 1407-1419.	2.5	83

#	ARTICLE	IF	CITATIONS
37	Selection of optimal reference genes for normalization in quantitative RT-PCR. <i>BMC Bioinformatics</i> , 2010, 11, 253.	2.6	81
38	<i>Escherichia coli</i> heat-stable toxin receptors in human colonic tumors. <i>Gastroenterology</i> , 1994, 107, 1653-1661.	1.3	80
39	Use of guanylyl cyclase c for detecting micrometastases in lymph nodes of patients with colon cancer. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 310-315.	1.3	79
40	A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4545-4552.	7.0	76
41	The Putative Tumor Suppressor Cdx2 Is Overexpressed by Human Colorectal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2005, 11, 8549-8556.	7.0	74
42	Mechanisms of Weight Regain following Weight Loss. <i>ISRN Obesity</i> , 2013, 2013, 1-7.	2.2	74
43	Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. <i>Gastroenterology</i> , 2000, 119, 89-96.	1.3	73
44	Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. <i>Gut</i> , 2018, 67, 1543-1552.	12.1	72
45	GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity. <i>PLoS ONE</i> , 2012, 7, e31686.	2.5	71
46	Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 573-585.	2.0	69
47	Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. <i>Cancer Research</i> , 2016, 76, 339-346.	0.9	64
48	Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 348-352.	4.7	63
49	Dexamethasone-Loaded Block Copolymer Nanoparticles Induce Leukemia Cell Death and Enhance Therapeutic Efficacy: A Novel Application in Pediatric Nanomedicine. <i>Molecular Pharmaceutics</i> , 2013, 10, 2199-2210.	4.6	63
50	The Paracrine Hormone Hypothesis of Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 441-447.	4.7	61
51	Atrial Natriuretic Factors Stimulate Accumulation and Efflux of Cyclic GMP in C6?2B Rat Glioma and PC12 Rat Pheochromocytoma Cell Cultures. <i>Journal of Neurochemistry</i> , 1987, 48, 522-528.	3.9	60
52	Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 701-713.	3.1	60
53	Tumor Epithelial Cell Matrix Metalloproteinase 9 Is a Target for Antimetastatic Therapy in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1876-1882.	7.0	60
54	Clinical and Translational Science: From Bench-Bedside to Global Village. <i>Clinical and Translational Science</i> , 2010, 3, 254-257.	3.1	60

#	ARTICLE	IF	CITATIONS
55	GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. <i>Oncolmmunology</i> , 2016, 5, e1227897.	4.6	59
56	Escherichia coli heat-stable enterotoxin receptors. <i>Diseases of the Colon and Rectum</i> , 1996, 39, 171-181.	1.3	57
57	Ectopic Expression of Guanylyl Cyclase C in CD34+Progenitor Cells in Peripheral Blood. <i>Journal of Clinical Oncology</i> , 2001, 19, 3951-3959.	1.6	56
58	Affinity purification of functional receptors for Escherichia coli heat-stable enterotoxin from rat intestine. <i>Biochemistry</i> , 1992, 31, 12-16.	2.5	55
59	Translating MicroRNA Discovery Into Clinical Biomarkers in Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1923.	7.4	55
60	The adipose tissue production of adiponectin is increased in end-stage renal disease. <i>Kidney International</i> , 2013, 83, 487-494.	5.2	55
61	Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 153-155.	4.7	52
62	Colorectal cancer immunotherapy. <i>Discovery Medicine</i> , 2013, 15, 301-8.	0.5	52
63	The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 67-72.	2.0	51
64	Obesity pharmacotherapy: What is next?. <i>Molecular Aspects of Medicine</i> , 2013, 34, 71-83.	6.4	50
65	The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2328-2337.	2.5	49
66	Guanylyl Cyclase Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity. <i>Journal of the National Cancer Institute</i> , 2008, 100, 950-961.	6.3	48
67	Identification and characterization of a new family of high-affinity receptors for Escherichia coli heat-stable enterotoxin in rat intestinal membranes. <i>Biochemistry</i> , 1991, 30, 10738-10745.	2.5	46
68	Contrast-Enhanced Ultrasound Imaging of Sentinel Lymph Nodes After Peritumoral Administration of Sonazoid in a Melanoma Tumor Animal Model. <i>Journal of Ultrasound in Medicine</i> , 2011, 30, 441-453.	1.7	46
69	MicroRNA Signatures as Diagnostic and Therapeutic Targets. <i>Clinical Chemistry</i> , 2008, 54, 943-944.	3.2	44
70	Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2268-2277.	0.7	43
71	Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. , 2019, 7, 104.		43
72	The involvement of catalytic site thiol groups in the activation of soluble guanylate cyclase by sodium nitroprusside. <i>Archives of Biochemistry and Biophysics</i> , 1986, 251, 709-714.	3.0	41

#	ARTICLE	IF	CITATIONS
73	Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 652-662.	4.7	41
74	Taking a Lesson From Microbial Diarrheagenesis in the Management of Chronic Constipation. <i>Gastroenterology</i> , 2010, 138, 813-817.	1.3	41
75	CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia. <i>Molecular Pharmaceutics</i> , 2015, 12, 2101-2111.	4.6	40
76	Regulation of Guanylate Cyclase by Atrial Natriuretic Factor and the Role of Cyclic GMP in Vasodilation. <i>American Journal of the Medical Sciences</i> , 1987, 294, 139-143.	1.1	38
77	Phosphorylation of vasodilator-estimated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. <i>International Journal of Cancer</i> , 2012, 130, 2539-2548.	5.1	38
78	Adenine nucleotide regulation of particulate guanylate cyclase from rat lung. <i>BBA - Proteins and Proteomics</i> , 1991, 1077, 99-106.	2.1	37
79	Regulation of Nitric Oxide-Responsive Recombinant Soluble Guanylyl Cyclase by Calcium. <i>Biochemistry</i> , 1999, 38, 6441-6448.	2.5	37
80	Selective antigen-specific CD4 <sup>+</sup> T cell, but not CD8 <sup>+</sup> or B cell, tolerance corrupts cancer immunotherapy. <i>European Journal of Immunology</i> , 2014, 44, 1956-1966.	2.9	37
81	The Guanylate Cyclase cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. <i>Frontiers in Oncology</i> , 2018, 8, 299.	2.8	37
82	In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand. <i>Journal of Nuclear Medicine</i> , 2002, 43, 392-9.	5.0	37
83	Guanylyl Cyclase C Prevents Colon Cancer Metastasis by Regulating Tumor Epithelial Cell Matrix Metalloproteinase-9. <i>Cancer Research</i> , 2009, 69, 3529-3536.	0.9	36
84	Guanylyl cyclase C signaling axis and colon cancer prevention. <i>World Journal of Gastroenterology</i> , 2016, 22, 8070.	3.3	36
85	Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease. <i>Cancer Research</i> , 2009, 69, 3537-3544.	0.9	35
86	Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. <i>Cancer Prevention Research</i> , 2017, 10, 345-354.	1.5	35
87	A Simple, Sensitive, and Specific Assay for the Heat-Stable Enterotoxin of <i>Escherichia coli</i> . <i>Journal of Infectious Diseases</i> , 1984, 149, 83-89.	4.0	34
88	Regulation of appetite to treat obesity. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 243-259.	3.1	34
89	Hypotensive Mechanisms of Amifostine. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 365-373.	2.0	33
90	Interruption of Homologous Desensitization in Cyclic Guanosine 3',5'-Monophosphate Signaling Restores Colon Cancer Cytostasis by Bacterial Enterotoxins. <i>Cancer Research</i> , 2005, 65, 11129-11135.	0.9	33

#	ARTICLE	IF	CITATIONS
91	Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity. <i>Nutrition and Diabetes</i> , 2016, 6, e211-e211.	3.2	33
92	Effects of atriopeptins on relaxation and cyclic GMP levels in human coronary artery in vitro. <i>European Journal of Pharmacology</i> , 1986, 124, 193-196.	3.5	32
93	Effect of Multiple Doses of Rifampin on the [ <sup>14</sup> C]-N-methyl Erythromycin Breath Test in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 492-495.	2.0	32
94	Therapeutic Targeting: A Crucible for Individualized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 651-654.	4.7	32
95	Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1250-1267.	3.7	32
96	Nitric oxide signaling: systems integration of oxygen balance in defense of cell integrity. <i>Current Opinion in Hematology</i> , 2004, 11, 7-14.	2.5	31
97	Proliferative Signaling by Store-Operated Calcium Channels Opposes Colon Cancer Cell Cytostasis Induced by Bacterial Enterotoxins. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1013-1022.	2.5	31
98	A Conserved Tissue-Specific Homeodomain-Less Isoform of MEIS1 Is Downregulated in Colorectal Cancer. <i>PLoS ONE</i> , 2011, 6, e23665.	2.5	31
99	Effects of atriopeptins on relaxation and cyclic GMP levels in rat and rabbit aortas. <i>European Journal of Pharmacology</i> , 1986, 120, 123-126.	3.5	30
100	The Guanylyl Cyclase Family of Natriuretic Peptide Receptors. <i>Vitamins and Hormones</i> , 1997, 57, 123-151.	1.7	30
101	Cytoplasmic Domains Mediate the Ligand-Induced Affinity Shift of Guanylyl Cyclase C. <i>Biochemistry</i> , 1997, 36, 12921-12929.	2.5	30
102	Indinavir and Rifabutin Drug Interactions in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 305-313.	2.0	30
103	Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. <i>Future Oncology</i> , 2009, 5, 509-522.	2.4	30
104	A study of microRNAs <i>in silico</i> and <i>in vivo</i> : diagnostic and therapeutic applications in cancer. <i>FEBS Journal</i> , 2009, 276, 2157-2164.	4.7	30
105	Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. <i>Human Pathology</i> , 2010, 41, 123-128.	2.0	30
106	Does potency predict clinical efficacy? Illustration through an antihistamine model. <i>Annals of Allergy, Asthma and Immunology</i> , 2002, 89, 7-12.	1.0	29
107	Clinical pharmacology: the science of therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 3-6.	4.7	29
108	Molecular Medicine Hones Therapeutic Arts to Science. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 343-347.	4.7	29

#	ARTICLE	IF	CITATIONS
109	Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics. <i>Toxins</i> , 2010, 2, 2028-2054.	3.4	29
110	Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1188-1195.	0.8	29
111	Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+T Cells. <i>Journal of Immunology</i> , 2017, 198, 3507-3514.	0.8	29
112	Atrial Natriuretic Peptide, Oxytocin, and Vasopressin Increase Guanosine 3'5'-Monophosphate in LLC-PK1 Kidney Epithelial Cells*. <i>Endocrinology</i> , 1988, 122, 1478-1485.	2.8	28
113	Losartan Does Not Affect the Pharmacokinetics and Pharmacodynamics of Warfarin. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 1008-1015.	2.0	28
114	Effect of Mibefradil on CYP3A4 In Vivo. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1091-1100.	2.0	28
115	Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor-associated Antigen. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 734-739.	4.7	28
116	Occult Tumor Burden Predicts Disease Recurrence in Lymph Node-Negative Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3293-3303.	7.0	28
117	Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 549-557.	3.1	28
118	Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase. <i>Molecular and Cellular Biochemistry</i> , 1983, 57, 155-166.	3.1	27
119	Atrial natriuretic peptides: Receptors and second messengers. <i>BioEssays</i> , 1989, 10, 16-19.	2.5	27
120	Effects of Food on the Bioequivalence of Different Verapamil Sustained-Release Formulations. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 163-169.	2.0	27
121	Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. <i>Infection and Immunity</i> , 2016, 84, 3083-3091.	2.2	27
122	Pharmacokinetics of Intramuscularly Administered Ertapenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1732-1735.	3.2	26
123	The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 697-703.	2.0	26
124	Health Care Evolves From Reactive to Proactive. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 10-13.	4.7	26
125	Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytoskeleton in colon cancer cells. <i>Carcinogenesis</i> , 2008, 29, 1601-1607.	2.8	25
126	Pharmacokinetics and Pharmacodynamics of Tepoxalin after Single Oral Dose Administration to Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 462-468.	2.0	24



#	ARTICLE	IF	CITATIONS
127	Individualized Medicine and the Imperative of Global Health. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 479-483.	4.7	24
128	Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 713-723.	4.2	24
129	Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea. <i>FASEB Journal</i> , 1999, 13, 913-922.	0.5	24
130	Interruption of Escherichia coli Heat-stable Enterotoxin-induced Guanylyl Cyclase Signaling and Associated Chloride Current in Human Intestinal Cells by 2-Chloroadenosine. <i>Journal of Biological Chemistry</i> , 1997, 272, 754-758.	3.4	23
131	Comparative disposition of [ <sup>14</sup> C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. <i>Xenobiotica</i> , 2004, 34, 379-389.	1.1	23
132	Relative quantification based on logistic models for individual polymerase chain reactions. <i>Statistics in Medicine</i> , 2007, 26, 5596-5611.	1.6	23
133	Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. <i>ESC Heart Failure</i> , 2020, 7, 3345-3354.	3.1	23
134	Cardiovascular Health: The Global Challenge. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 483-485.	4.7	22
135	New advances in models and strategies for developing anti-obesity drugs. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 655-671.	5.0	22
136	Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. <i>Human Gene Therapy Methods</i> , 2016, 27, 238-250.	2.1	22
137	GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?. <i>Drug News and Perspectives</i> , 2009, 22, 313.	1.5	22
138	GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. <i>Oncotarget</i> , 2014, 5, 9460-9471.	1.8	22
139	Characterization of etoricoxib, a novel, selective COX-2 inhibitor. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 573-85.	2.0	22
140	Colorectal Cancer Is a Paracrine Deficiency Syndrome Amenable to Oral Hormone Replacement Therapy. <i>Clinical and Translational Science</i> , 2008, 1, 163-167.	3.1	21
141	Molecular Therapeutics From Knowledge to Delivery. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 619-623.	4.7	21
142	GUCY2C: at the intersection of obesity and cancer. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 165-173.	7.1	21
143	Intestinal GUCY2C Prevents TGF- $\beta$ Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer. <i>Cancer Research</i> , 2013, 73, 6654-6666.	0.9	21
144	Nitric Oxide Activation of Soluble Guanylyl Cyclase Reveals High and Low Affinity Sites That Mediate Allosteric Inhibition by Calcium. <i>Biochemistry</i> , 2002, 41, 3396-3404.	2.5	20

#	ARTICLE	IF	CITATIONS
145	Functional and Molecular Characterization of $\hat{\mu}^2$ -Adrenoceptors in the Internal Anal Sphincter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 615-624.	2.5	20
146	Translational medicine: path to personalized and public health. <i>Biomarkers in Medicine</i> , 2010, 4, 787-790.	1.4	20
147	The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1125-1131.	2.0	19
148	Myeloid-specific deletion of Zfp36 protects against insulin resistance and fatty liver in diet-induced obese mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E676-E693.	3.5	19
149	Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin. <i>Brain Structure and Function</i> , 2019, 224, 2983-2999.	2.3	19
150	Solubilization and characterization of functionally coupled Escherichia coli heat-stable toxin receptors and particulate guanylate cyclase associated with the cytoskeleton compartment of intestinal membranes. <i>International Journal of Biochemistry &amp; Cell Biology</i> , 1993, 25, 557-566.	0.5	18
151	An Intracellular Adenine Nucleotide Binding Site Inhibits Guanylyl Cyclase C by a Guanine Nucleotide-Dependent Mechanism. <i>Biochemistry</i> , 1996, 35, 3213-3221.	2.5	18
152	Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2004, 43, 121-129.	3.5	18
153	Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. <i>Analytical Biochemistry</i> , 2006, 348, 198-208.	2.4	18
154	Molecular staging individualizing cancer management. <i>Journal of Surgical Oncology</i> , 2012, 105, 468-474.	1.7	18
155	Molecular Staging of Node Negative Patients with Colorectal Cancer. <i>Journal of Cancer</i> , 2013, 4, 193-199.	2.5	18
156	Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia. <i>Human Pathology</i> , 2019, 87, 103-114.	2.0	18
157	A common antigenic determinant found in two functionally unrelated toxins.. <i>Journal of Experimental Medicine</i> , 1984, 160, 1253-1258.	8.5	17
158	Rat Guanylyl Cyclase C Expressed in COS-7 Cells Exhibits Multiple Affinities for Escherichia coli Heat-Stable Enterotoxin. <i>Biochemistry</i> , 1995, 34, 9095-9102.	2.5	17
159	Colorectal cancer staging and adjuvant chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 737-755.	1.8	17
160	Nucleotide requirements for CDX2 binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C. <i>FEBS Letters</i> , 2001, 507, 128-132.	2.8	17
161	Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. <i>Future Oncology</i> , 2006, 2, 705-716.	2.4	17
162	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2454-2456.	2.8	17

#	ARTICLE	IF	CITATIONS
163	Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 739-44.	2.5	17
164	Rat intestinal cell atrial natriuretic peptide receptor coupled to guanylate cyclase. <i>Gastroenterology</i> , 1990, 99, 125-131.	1.3	16
165	GUCY2C ligand replacement to prevent colorectal cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 713-718.	3.4	16
166	Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. , 2020, 8, e001046.		16
167	Relationship of Arachidonic Acid Concentration to Cyclooxygenase-Dependent Human Platelet Aggregation. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 983-989.	2.0	15
168	A 56 kDa binding protein for Escherichia coli heat-stable enterotoxin isolated from the cytoskeleton of rat intestinal membranes does not possess guanylate cyclase activity. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1993, 1152, 1-8.	2.6	14
169	Pharmacoeconomics in the Era of Individualized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 179-182.	4.7	14
170	Translational Medicine in the Era of Health Care Reform. <i>Clinical and Translational Science</i> , 2009, 2, 96-97.	3.1	14
171	Knowledge Cycle Transforms Therapeutic Innovation. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 3-8.	4.7	14
172	Guanylyl cyclase C as a biomarker in colorectal cancer. <i>Biomarkers in Medicine</i> , 2013, 7, 159-167.	1.4	14
173	Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. <i>Journal of Cancer</i> , 2013, 4, 172-192.	2.5	14
174	Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer. <i>Molecular Pharmacology</i> , 2016, 90, 199-204.	2.3	14
175	ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice. <i>Toxins</i> , 2017, 9, 279.	3.4	14
176	Regulation of Cyclic GMP Synthesis and the Interactions with Calcium. <i>Journal of Cardiovascular Pharmacology</i> , 1986, 8, S57-S60.	1.9	13
177	Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1190-1196.	4.1	13
178	Clinical Pharmacology as a Foundation for Translational Science. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 10-13.	4.7	13
179	Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. <i>Cancer</i> , 2012, 118, 2532-2540.	4.1	13
180	Silencing the intestinal GUCY2C tumor suppressor axis requires <i>APC</i> loss of heterozygosity. <i>Cancer Biology and Therapy</i> , 2020, 21, 799-805.	3.4	13

#	ARTICLE	IF	CITATIONS
181	TUMOR-TARGETING PEPTIDE-PNA-PEPTIDE CHIMERAS FOR IMAGING OVEREXPRESSED ONCOGENE mRNAs. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1085-1091.	1.1	12
182	Experimental Therapeutics: A Paradigm for Personalized Medicine. Clinical and Translational Science, 2009, 2, 436-438.	3.1	12
183	<scp>Hot Topic</scp>: Molecular Therapy Drives Patientâ€Centric Health Care Paradigms. Clinical and Translational Science, 2010, 3, 170-171.	3.1	12
184	A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients. , 2015, 3, .		12
185	Companion diagnostics at the intersection of personalized medicine and healthcare delivery. Biomarkers in Medicine, 2015, 9, 1-3.	1.4	12
186	GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Research, 2017, 77, 5095-5106.	0.9	12
187	T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C. Frontiers in Immunology, 2022, 13, 855759.	4.8	12
188	Regulation of Particulate Guonylate Cyclase by Natriuretic Peptides and Escherichia coli Heat-Stable Enterotoxin. Advances in Pharmacology, 1994, 26, 67-86.	2.0	11
189	GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Review of Molecular Diagnostics, 2009, 9, 777-785.	3.1	11
190	Clinical pharmacology: a paradigm for individualized medicine. Biomarkers in Medicine, 2009, 3, 679-684.	1.4	11
191	Bile Acids Initiate Lineageâ€Addicted Gastroesophageal Tumorigenesis by Suppressing the EGF Receptorâ€AKT Axis. Clinical and Translational Science, 2009, 2, 286-293.	3.1	11
192	Patient-centric clinical pharmacology advances the path to personalized medicine. Biomarkers in Medicine, 2011, 5, 697-700.	1.4	11
193	Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Review of Clinical Pharmacology, 2013, 6, 557-564.	3.1	11
194	Soluble guanylate cyclase is allosterically inhibited by direct interaction with 2-substituted adenine nucleotides. FEBS Journal, 2002, 269, 2186-2193.	0.2	10
195	Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomarkers in Medicine, 2007, 1, 187-202.	1.4	10
196	Targeted diagnostics and therapeutics for individualized patient management. Biomarkers in Medicine, 2007, 1, 3-8.	1.4	10
197	Corruption of homeostatic mechanisms in the guanylyl cyclase c signaling pathway underlying colorectal tumorigenesis. Cancer Biology and Therapy, 2010, 10, 211-218.	3.4	10
198	Clinical Translational Science 2020: Disruptive Innovation Redefines the Discoveryâ€Application Enterprise. Clinical and Translational Science, 2011, 4, 69-71.	3.1	10

#	ARTICLE	IF	CITATIONS
199	GUCY2C-targeted cancer immunotherapy: past, present and future. <i>Immunologic Research</i> , 2011, 51, 161-169.	2.9	10
200	Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy. <i>Journal of Clinical Medicine</i> , 2014, 3, 763-794.	2.4	10
201	APC- $\beta$ -catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. <i>Cancer Biology and Therapy</i> , 2020, 21, 441-451.	3.4	10
202	Advances in cancer immunotherapy. <i>Discovery Medicine</i> , 2013, 15, 120-5.	0.5	10
203	Manufacturer's Drug Interaction and Postmarketing Adverse Event Data. <i>Drug Safety</i> , 2001, 24, 637-643.	3.2	9
204	A Comparative Molecular Field Analysis (COMFA) of the Structural Determinants of Heat-Stable Enterotoxins Mediating Activation of Guanylyl Cyclase C. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1731-1734.	6.4	9
205	Applications of MicroRNA in Cancer: Exploring the Advantages of miRNA. <i>Clinical and Translational Science</i> , 2009, 2, 248-249.	3.1	9
206	Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. <i>Journal of Surgical Oncology</i> , 2012, 106, 24-30.	1.7	9
207	Systems-Based Discovery Advances Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 285-287.	4.7	9
208	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. <i>Biomarkers in Medicine</i> , 2013, 7, 23-35.	1.4	9
209	Policies to aid the adoption of personalized medicine. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 159-160.	46.4	9
210	Big Data Transforms Discovery's Utilization Therapeutics Continuum. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 250-254.	4.7	9
211	Therapeutic targeting of gastrointestinal cancer stem cells. <i>Regenerative Medicine</i> , 2019, 14, 331-343.	1.7	9
212	Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. <i>American Journal of Gastroenterology</i> , 2022, 117, S6-S13.	0.4	9
213	Sensitivity in detecting drug-induced alterations in the PR interval: Comparison of the surface electrocardiogram measured by a cardiologist versus routine automated computer analysis. <i>American Journal of Cardiology</i> , 1993, 72, 834-836.	1.6	8
214	Binding characteristics of <i>Ustilago maydis</i> topoisomerase I to DNA containing secondary structures. <i>FEBS Journal</i> , 1998, 255, 347-355.	0.2	8
215	H-ras Inhibits RhoA/ROCK Leading to a Decrease in the Basal Tone in the Internal Anal Sphincter. <i>Gastroenterology</i> , 2007, 132, 1401-1409.	1.3	8
216	Cytokine Adjuvination of Therapeutic Anti-tumor Immunity Targeted to Cancer Mucosa Antigens. <i>Clinical and Translational Science</i> , 2008, 1, 263-264.	3.1	8

#	ARTICLE	IF	CITATIONS
217	Previstage <sup>®</sup> , <sup>®</sup> GCC test for staging patients with colorectal cancer. Expert Review of Molecular Diagnostics, 2008, 8, 571-578.	3.1	8
218	Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer. Biomarkers in Medicine, 2009, 3, 33-45.	1.4	8
219	Widening the Path to Personalized Medicine. Clinical and Translational Science, 2011, 4, 392-394.	3.1	8
220	Advancing Pharmacometrics and Systems Pharmacology. Clinical Pharmacology and Therapeutics, 2012, 92, 535-537.	4.7	8
221	The Value Proposition of Molecular Medicine. Clinical and Translational Science, 2012, 5, 108-110.	3.1	8
222	Translational medicine individualizes healthcare discovery, development and delivery. Biomarkers in Medicine, 2013, 7, 1-3.	1.4	8
223	Managing the Innovation Supply Chain to Maximize Personalized Medicine. Clinical Pharmacology and Therapeutics, 2014, 95, 113-118.	4.7	8
224	Bioinnovation Enterprise: An engine driving breakthrough therapies. Clinical Pharmacology and Therapeutics, 2016, 99, 8-13.	4.7	8
225	NHERF3 is necessary for <i>Escherichia coli</i> heat-stable enterotoxin-induced inhibition of NHE3: differences in signaling in mouse small intestine and Caco-2 cells. American Journal of Physiology - Cell Physiology, 2019, 317, C737-C748.	4.6	8
226	Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation. Clinical and Translational Gastroenterology, 2019, 10, e00016.	2.5	8
227	GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress. Oncotarget, 2017, 8, 102923-102933.	1.8	8
228	Regulation of particulate guanylatecylase by <i>Escherichia coli</i> heat-stable enterotoxin: Receptor binding and enzyme kinetics. International Journal of Biochemistry & Cell Biology, 1989, 21, 1211-1215.	0.5	7
229	Human cholecystokinin-A receptor is not an oncofetal protein. Digestive Diseases and Sciences, 2000, 45, 538-543.	2.3	7
230	STa peptide analogs for probing guanylyl cyclase C. Biopolymers, 2008, 90, 713-723.	2.4	7
231	Clinical and Translational Sciences: At the Intersection of Molecular and Individualized Medicine. Clinical and Translational Science, 2008, 1, 6-8.	3.1	7
232	Information Hierarchies Optimize Patient-Centered Solutions. Clinical Pharmacology and Therapeutics, 2013, 93, 3-7.	4.7	7
233	Does obesity promote the development of colorectal cancer?. Expert Review of Anticancer Therapy, 2016, 16, 465-467.	2.4	7
234	Association of Inflammation prior to Kidney Transplantation with Post-Transplant Diabetes Mellitus. CardioRenal Medicine, 2016, 6, 289-300.	1.9	7

#	ARTICLE	IF	CITATIONS
235	Managing Innovation to Maximize Value Along the Discoveryâ€Translationâ€Application Continuum. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 8-12.	4.7	7
236	An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1125-1137.	3.1	7
237	Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 335-346.	3.4	7
238	Cyclic Nucleotides and Protein Phosphorylation in Vascular Smooth-Muscle Relaxation. <i>Developments in Cardiovascular Medicine</i> , 1989, , 825-846.	0.1	7
239	Where medicine, business, and public policy intersect. <i>Biotechnology Healthcare</i> , 2007, 4, 33-42.	0.2	7
240	Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. <i>American Journal of Gastroenterology</i> , 2022, 117, S21-S26.	0.4	7
241	[36] Immunoaffinity purification of soluble guanylyl cyclase. <i>Methods in Enzymology</i> , 1991, 195, 391-396.	1.0	6
242	[41] Identification of atrial natriuretic peptide receptors in cultured cells. <i>Methods in Enzymology</i> , 1991, 195, 436-446.	1.0	6
243	Intestinal Kinetics And Dynamics Of Escherichia Coli Heat-Stabile Enterotoxin In Suckling Mice. <i>Journal of Infectious Diseases</i> , 1994, 170, 1498-1507.	4.0	6
244	Paradoxical Hypotension and Bradycardia after Intravenous Arginine Vasopressin. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 283-286.	2.0	6
245	Adverse Drug Reactions: A Review. <i>Drug Information Journal</i> , 1998, 32, 323-338.	0.5	6
246	The Roadmap to Personalized Medicine. <i>Clinical and Translational Science</i> , 2008, 1, 93-93.	3.1	6
247	Molecular Insights Provide the Critical Path to Disease Mitigation. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 95, 3-7.	4.7	6
248	A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients. <i>BMC Cancer</i> , 2016, 16, 766.	2.6	6
249	First-in-Human Use of a Retention-Enhanced Catheter for Endomyocardial Cell Delivery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 412-414.	2.9	6
250	Modeling qRT-PCR dynamics with application to cancer biomarker quantification. <i>Statistical Methods in Medical Research</i> , 2018, 27, 2581-2595.	1.5	6
251	TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C. <i>Journal of Immunology</i> , 2019, 202, 1301-1310.	0.8	6
252	Stem cells as therapeutic targets in colorectal cancer. <i>Personalized Medicine</i> , 2021, 18, 171-183.	1.5	6



#	ARTICLE	IF	CITATIONS
253	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 117-129.	0.7	6
254	Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biology and Therapy, 2021, 22, 544-553.	3.4	6
255	A $\beta$ -Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1276-1296.	4.5	6
256	Regulation of particulate guanylate cyclase by atriopeptins: relation between peptide structure, receptor binding, and enzyme kinetics. BBA - Proteins and Proteomics, 1989, 999, 157-162.	2.1	5
257	Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End-Stage Renal Insufficiency. Journal of Clinical Pharmacology, 2000, 40, 745-751.	2.0	5
258	A splice variant of the transcript for guanylyl cyclase C is expressed in human colon and colorectal cancer cells. Digestive Diseases and Sciences, 2000, 45, 298-305.	2.3	5
259	Acquired and innate cardioprotection. Journal of Applied Physiology, 2007, 103, 1436-1437.	2.5	5
260	The Merck Manual, 18th Edition. Clinical Pharmacology and Therapeutics, 2007, 81, 790-791.	4.7	5
261	Chemiluminescence-based detection of gastrointestinal malignancies. Luminescence, 2010, 25, 463-465.	2.9	5
262	Systems Approaches Evolve Clinical Pharmacology. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-2.	2.5	5
263	Process Improvement for Maximized Therapeutic Innovation Outcome. Clinical Pharmacology and Therapeutics, 2018, 103, 8-12.	4.7	5
264	The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission. Expert Opinion on Biological Therapy, 2021, 21, 1335-1345.	3.1	5
265	Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. Npj Vaccines, 2022, 7, .	6.0	5
266	Pathological staging and therapy of oesophageal and gastric cancer. Expert Opinion on Pharmacotherapy, 2003, 4, 1083-1096.	1.8	4
267	Molecular Diagnostics. Clinical and Translational Science, 2009, 2, 6-8.	3.1	4
268	Molecular Staging Estimates Occult Tumor Burden in Colorectal Cancer. Advances in Clinical Chemistry, 2010, 52, 19-39.	3.7	4
269	Clinical pharmacology at the core of translational science. Expert Review of Clinical Pharmacology, 2011, 4, 303-305.	3.1	4
270	A Novel CDX2 Isoform Regulates Alternative Splicing. PLoS ONE, 2014, 9, e104293.	2.5	4



#	ARTICLE	IF	CITATIONS
271	Emerging drug targets for colon cancer: A preclinical assessment. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 207-216.	3.4	4
272	Comparison of particulate guanylate cyclase in cells with and without atrial natriuretic peptide receptor binding activity. <i>Molecular and Cellular Biochemistry</i> , 1989, 90, 19-25.	3.1	3
273	Derivation and Fluidity of Acutely Induced Dysfunctional CD8+ T Cells. <i>Journal of Immunology</i> , 2008, 180, 5300-5308.	0.8	3
274	Sizing Up Pharmacotherapy for Obesity. <i>Clinical and Translational Science</i> , 2010, 3, 123-125.	3.1	3
275	Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 765-783.	2.4	3
276	Bionic Technologies Transforming the Science of Healthcare Delivery. <i>Clinical and Translational Science</i> , 2011, 4, 84-86.	3.1	3
277	GUCY2C molecular staging personalizes colorectal cancer patient management. <i>Biomarkers in Medicine</i> , 2012, 6, 339-348.	1.4	3
278	The orl rat is more responsive to methacholine challenge than wild type. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 29, 199-208.	2.6	3
279	Clinical Pharmacology & Therapeutics: The Next Five Years. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 2-6.	4.7	3
280	Clinical Pharmacology & Therapeutics: Past, Present, and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 300-303.	4.7	3
281	Prenatal Regeneration in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2018, 93, 673-675.	3.0	3
282	Biomarker targeting of colorectal cancer stem cells. <i>Biomarkers in Medicine</i> , 2019, 13, 891-894.	1.4	3
283	Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase. <i>Molecular and Cellular Biochemistry</i> , 1983, 57, 155.	3.1	3
284	Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 573-585.	2.0	3
285	Allosteric regulation by calcium of rabbit polyclonal anti-cyclic GMP antibody. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1995, 1243, 143-150.	2.4	2
286	The Molecular Therapeutics Section of the American Society for Clinical Pharmacology and Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 336-337.	4.7	2
287	Markers of Cell Cycle-Mediated Drug Resistance And Prognosis Of Patients Receiving Preoperative Combined Modality Therapy For Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2004, 11, 949-950.	1.5	2
288	Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 27-37.	3.1	2

#	ARTICLE	IF	CITATIONS
289	Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. <i>Histopathology</i> , 2009, 55, 182-188.	2.9	2
290	Colorectal cancer stem cells as biomarkers: Where it all starts?. <i>Journal of Surgical Oncology</i> , 2013, 107, 791-793.	1.7	2
291	Editorial (Thematic Issue: Ferid Murad, at 80: A Legacy of Science, Medicine, and Mentorship). <i>Current Medicinal Chemistry</i> , 2016, 23, 2556-2558.	2.4	2
292	[37] Copurification of atrial natriuretic peptide receptor and particulate guanylyl cyclase. <i>Methods in Enzymology</i> , 1991, 195, 397-404.	1.0	1
293	Reciprocal Regulation and Integration of Signaling by Intracellular Calcium and Cyclic GMP. <i>Vitamins and Hormones</i> , 2004, 69, 69-94.	1.7	1
294	Therapeutic burden in cancer revealed by molecular staging. <i>Biomarkers in Medicine</i> , 2008, 2, 1-3.	1.4	1
295	Transitioning biomarkers into the clinic. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 9-13.	3.1	1
296	Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. <i>Biomarkers in Medicine</i> , 2021, 15, 201-217.	1.4	1
297	Targeting guanylate cyclase C in colorectal cancer: Where are we now?. <i>Drugs of the Future</i> , 2016, 41, 0477.	0.1	1
298	CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS. <i>BIOforum Europe: Trends and Techniques in Life Science Research</i> , 2009, 3, 14-16.	0.0	1
299	GUCY2C-Enriched Intestinal Neuropod Cells Modulate Visceral Pain. <i>FASEB Journal</i> , 2022, 36, .	0.5	1
300	Evolution of Clinical Pharmacology and Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 233-235.	4.7	0
301	Sex Modulates Intestinal Transformation by the Tumor-Suppressor GCC. <i>Clinical and Translational Science</i> , 2008, 1, 150-150.	3.1	0
302	Sex Modulates Intestinal Transformation by the Tumor-Suppressor GCC. <i>Clinical and Translational Science</i> , 2008, 1, 146-150.	3.1	0
303	Bridging the therapeutic continuum of drug development, regulation and use. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 1-3.	3.1	0
304	MicroRNA Signatures as Diagnostic and Therapeutic Targets. <i>Laboratory Medicine Online</i> , 2011, 1, 1.	0.2	0
305	Clinical Pharmacology & Therapeutics 2011: Year in Review. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 353-357.	4.7	0
306	P1p1 gene duplication inhibits airway responsiveness and induces lung inflammation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 30, 22-31.	2.6	0

#	ARTICLE	IF	CITATIONS
307	Peer Review Certifies Quality and Innovation in <i>Clinical Pharmacology & Therapeutics</i>. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 373-377.	4.7	0
308	From leptin to lasers: the past and present of mouse models of obesity. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 777-790.	5.0	0
309	Emerging targets for the diagnosis of Parkinsonâ€™s disease: examination of systemic biomarkers. <i>Biomarkers in Medicine</i> , 2021, 15, 597-608.	1.4	0
310	Cyclic Nucleotides and Protein Phosphorylation in Vascular Smooth Muscle Relaxation. , 2001, , 805-828.		0
311	PHARMACOTHERAPEUTIC CONTINUUM: ENGINEERING THE FUTURE OF INDIVIDUALIZED MEDICINE. , 2009, , 3-5.		0
312	The Novel Role of Guanylyl Cyclase C Signaling in Appetite Suppression and Body Weight Regulation. <i>FASEB Journal</i> , 2009, 23, LB365.	0.5	0
313	Effect of a novel CDX2 splice variant on tumorigenicity in gastroesophageal junction adenocarcinoma xenografts.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14619-e14619.	1.6	0
314	Guanylyl Cyclase C as Biomarker. , 2014, , 1-16.		0
315	Guanylyl Cyclase C as a Biomarker. <i>Biomarkers in Disease</i> , 2015, , 363-381.	0.1	0
316	Calorieâ€induced ER Stress Silences the Guanylinâ€GUCY2C Paracrine Axis Underlying Colorectal Cancer in Obesity. <i>FASEB Journal</i> , 2015, 29, LB542.	0.5	0
317	Guanylate cyclase C (GUCY2C) as a preventative and therapeutic target in colorectal cancers (CRCs) arising through divergent genomic pathways.. <i>Journal of Clinical Oncology</i> , 2019, 37, 595-595.	1.6	0
318	A â€cateninâ€CFâ€sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer. <i>FASEB Journal</i> , 2022, 36, .	0.5	0